Arecoline hydrobromide is a nicotinic acids-based alkaloid and partial agonist of muscarinic acetylchiline M1, M2, M3 and M4 receptors. The LD50 of subcutaneous injection value is 100 mg/kg in mouse [1].
Arecoline hydrobromide has been suggested to have electrophysiological effects on ventricular myocytes. Arecoline hydrobromide has shown the significant inhibitory effect on hERG current with the IC50 value of 9.55μmol/L. Furthermore, Arecoline hydrobromide has demonstrated the concentration- , time- and voltage-dependent characteristics of IhERG inhibition in the patch clamp experiments. Apart from these, Arecoline hydrobromide has been exhibited to significant change in the amount of steady-state blockade at stimulation frequencies. It has been shown frequency-dependent characteristics inhibition of IhERG by Arecoline hydrobromide [1].
References:
[1] Zhao XY1, Liu YQ, Fu YC, Xu B, Gao JL, Zheng XQ, Lin M, Chen MY, Li Y. Frequency- and state-dependent blockade of human ether-a-go-go-related gene K+ channel by arecoline hydrobromide. Chin Med J (Engl). 2012 Mar;125(6):1068-75.